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Background: Sarcoidosis is still considered a rare multisystem disorder in Taiwan, and data on the disease
course and outcome are limited. We analyzed the clinical manifestations, disease course and complications
in Taiwanese patients with sarcoidosis.
Methods: A retrospective cohort design was used. Fifty-six patients with sarcoidosis diagnosed between 1985
and 2004 were included. Their clinical features, laboratory findings at initial presentation, disease course,
and complications were analyzed.
Results: Forty-three patients (76.8%) were female. The mean age at symptom onset was 47 years. The most
common clinical symptoms were pulmonary (82.1%), cutaneous (23.2%), ophthalmic (19.6%), and articular
(17.8%). Only two patients presented with Löfgren’s syndrome. There was a seasonal variation in disease
onset, with higher incidence in winter and early spring. No advanced pulmonary involvement was noted.
Elevated levels of serum angiotensin converting enzyme (sACE) were found in 72.5% (29/40) of patients
with active sarcoidosis, and significantly higher levels of sACE were found in patients with lung involvement
(27.98 ± 1.71 IU/L vs. 18.2 ± 2.76 IU/L; p < 0.01). In 50% (20/40) of patients, sACE levels declined significantly
in parallel with clinical remission (24.75 ± 1.53 IU/L vs. 16.33 ± 1.21 IU/L; p < 0.05). Spontaneous complete
remission was found in 20.7% of patients, whereas 39.6% of patients with multiple extrapulmonary
involvement responded poorly to intensive corticosteroids plus various immunosuppressants.
Conclusion: In this series, the mean age of disease onset was in middle age (mean, 47 years old), there was a
low incidence of Löfgren’s syndrome (3.6%), and no patients had advanced pulmonary syndrome. The results
of this study also suggest that sACE might be a marker of pulmonary involvement that is also useful in
monitoring disease activity. [J Formos Med Assoc 2006;105(4):269–276]
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Sarcoidosis is a systemic disorder of unknown cause
characterized by its pathologic hallmark, the non-
caseating granuloma.1 This disease can be self-
limiting or chronic, with episodic recrudescence
and remission.1 Most patients report either acute
or insidious respiratory problems, variably accom-
panied by symptoms affecting the skin, eyes, or
other organs. Sarcoidosis occurs worldwide, affect-
ing persons of all races and ages, and both genders.
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It has a particular proclivity for adults under the
age of 40 and for certain ethnic and racial groups.1
The reported prevalence of sarcoidosis ranges
from less than 1 case to 40 cases per 100,000 popu-
lation, with an age-adjusted annual incidence
in the United States of 10.9 per 100,000 for whites
and 35.5 per 100,000 for blacks.1,2 In Taiwan, sar-
coidosis is still considered a rare disease, although
Perng et al reported increasing incidence in recent
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Clinical method
A retrospective cohort design was used. Informa-
tion about the clinical manifestations and disease
course of all patients were collected, using stan-
dardized definitions and a standardized data ex-
traction form. Chest radiography was performed
at the time of initial diagnosis. Staging used
the modified Scadding system6 as follows: stage
0, normal; stage I, bilateral hilar lymphadeno-
pathy; stage II, hilar lymphadenopathy with pul-
monary infiltration; stage III, pulmonary infiltra-
tion only; and stage IV, end-stage pulmonary
fibrosis.
Measurement of sACE level and gallium-67
scan were conducted in only 40 patients at initial
diagnosis. Gallium-67 scan was also performed in
those patients with hilar enlargement on chest
radiograph. ACE was measured by the colorimet-
ric method (ACE color; Fujirebio Diagnostics Inc,
Tokyo, Japan). The clinical disease activity of
sarcoidosis was defined as described previously
(Table 1).6 The decision to treat was based on the
following criteria: (1) progressive change on chest
radiographs or diffuse pulmonary involvement;
(2) impairment of organs other than the lungs;
and (3) persistent symptoms combined with para-
meters indicative of disease activity. Medication
was given with corticosteroids, disease-modifying
anti-rheumatic drugs (DMARDs) including metho-
trexate, and/or other immunosuppressive agents
as necessary.
Follow-up study
The average follow-up duration was 7.2 years
(range, 1–20 years). Fifty-three of 56 patients with
sarcoidosis underwent repeat chest radiography
at least every 6 months during the follow-up peri-
od after diagnosis. Complete remission was defined
as normalization of chest radiograph and resolu-
tion of clinical manifestations, including the
cutaneous, ocular and articular involvement. Par-
tial remission was defined as unchanged or im-
proved chest radiograph findings, defined as stage
* 1, and/or stabilized clinical manifestations. Per-
sistent course was defined as deterioration of chest
radiograph findings, defined as * 1 stage worsen-
years, from 0.25 per 100,000 admissions to 2.7
per 100,000 admissions.3 Data about the disease
course and outcome of sarcoidosis in Taiwan are
limited. Ever since Liberman first reported eleva-
tions of serum angiotensin converting enzyme
(sACE) activity in sarcoidosis patients,4 efforts
have been made to determine its role in this in-
flammatory disease. The levels of sACE may col-
late with radiologic and clinical abnormalities,4
but few studies have examined its relationship with
clinical manifestations.
This study analyzed the clinical manifestations
and laboratory findings at initial presentation, the
disease course, and prognosis of 56 patients with
sarcoidosis, and investigated the relationship be-
tween sACE and clinical manifestations and
prognosis.
Methods
Patients
Fifty-six patients with sarcoidosis diagnosed at
Taichung Veterans General Hospital between Jan-
uary 1985 and January 2004 were included. The
diagnosis was established in accordance with the
following criteria:5 (1) histologic evidence of non-
caseating granulomas in affected tissues; (2) clini-
cal signs or symptoms consistent with sarcoidosis,
that is, bilateral hilar lymphadenopathy and ery-
thema nodosum and/or arthritis. Individuals with
fungal disease, active tuberculosis, or who were
taking antituberculosis therapy were excluded. This
study was approved by the institutional review
board of Taichung Veterans General Hospital.
Table 1. Criteria of sarcoidosis activity*
- Clinical features consistent with sarcoidosis†
- Abnormalities on chest radiograph (mediastinal lymphadenopathy or
pulmonary infiltration)
- Increased serum angiotensin converting enzyme level
- Increased gallium-67 scan uptake (or liver uptake)
*Presence of, or changes in, any of the listed criteria constitutes evidence of disease
activity; †skin lesions (erythema nodosum or granulomas), polyarthralgia/arthritis,
respiratory symptoms (cough, dyspnea), fever, uveitis, hepatosplenomegaly, parotid
enlargement, upper respiratory tract involvement, neurologic symptoms.
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ing at the end of the follow-up period, or persist-
ent or progressive clinical symptoms without re-
sponse to treatment. Relapse was defined as de-
terioration of chest radiograph findings after
stabilization for 6 months or worsening of clini-
cal symptoms after resolution or stabilization for
6 months. In patients with complete or partial re-
mission, the average period of sACE measurement
was 6 months after the patient was symptom-free
or in a stable condition. In patients with relapse,
the average period of sACE measurement was 1
month after symptoms progressed.
Statistical analysis
Results were expressed as mean ± SEM unless
otherwise specified. Differences among groups
were determined by the Kruskal-Wallis test for
nonparametric analysis of variance. Correlations
among different variables were determined with
multiple logistic regression. The Wilcoxon signed-
rank test was used for comparison of sACE levels
during follow-up. All statistical analyses were per-
formed with SPSS version 10.0 (SPSS Inc, Chicago,
IL, USA) for Windows.
Results
The demographic characteristics and clinical man-
ifestations of sarcoidosis in the 56 patients are
shown in Table 2,7–10 while the organs involved
are shown in Table 3.
Demographic characteristics
The study cohort comprised 13 men and 43
women. The mean age at disease onset was 38
years in men, 50 years in women and 47 years
(range, 18–76 years) in all patients. Thirty-six pa-
tients (64.3%) were aged 40–70 years at disease
onset, four (7.1%) were > 70 years old, and 16
(28.6%) were < 40 years old. There was a seasonal
variation in disease onset, with a higher incidence
Table 2. Demographic data and clinical manifestations of sarcoidosis patients in this and previously reported series
This series Reynolds7 Baughman et al8 Pietinalho et al
9
Wang et al10
(n = 56) (n = 67) (n = 736) (n = 245) (n = 189) (n = 25)
Female (%) 76.8 59.7 63.6 67.0 60.0 52.0
Country of origin Taiwan USA USA Japan Finland China
Age at presentation < 40 yr (%) 28.6 58.0 54.0 N/A N/A 40.0
Mean age at onset (yr) 47.0 38.7 36.0 41.5 30.0 47.2
Chest radiograph (%)
Stage 0 17.8 01.5 08.3 18.0 01.0 12.0
Stage I 53.6 59.0 39.7 57.0 48.0 28.0
Stage II 28.6 32.0 36.7 20.0 39.0 56.0
Stage III 00.0 00.0 09.8 05.0 12.0 04.0
Stage IV 00.0 09.0 05.4 00.0 00.0 00.0
Clinical manifestations (%)
Pulmonary symptoms 82.1 98.0 95.0 03.0 33.0 88.0
Skin 26.8 36.0 24.2 00.0 18.0 36.0
Eyes 19.6 09.0 11.8 41.0 05.0 04.0
Arthralgia/arthritis 17.8 13.4 00.5 16.0 16.0 08.0
Hypercalcemia 20.0 18.0 03.7 N/A N/A 11.0
Heart 01.8 09.0 02.3 N/A N/A N/A
Neurologic system 01.8 09.0 04.6 N/A N/A N/A
Löfgren’s syndrome 03.6 09.0 N/A N/A N/A N/A
N/A = not available.
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(66.3%) in winter and early spring, and a lower
incidence (18.8%) in autumn.
Clinical presentation
The most common manifestations were respira-
tory, cutaneous, ocular and articular symptoms
(Table 2). There were seven (12.5%) asymptomat-
ic patients, who were identified by routine chest
radiography during physical check-up. Three of
the 56 patients also had constitutional symptoms,
i.e. fever, fatigue and body weight loss.
Pulmonary manifestations
Isolated pulmonary involvement was found in
25 patients (44.6%) (Table 3). Twenty-six (46.4%)
patients presented with pulmonary symptoms,
including cough, exertional dyspnea and chest
tightness. Pulmonary symptoms were associated
with extrathoracic manifestations in 24 (42.9%)
patients, including joint pain, ocular involvement
and cutaneous lesions. The distribution of staging
of the chest radiographs is summarized in Table
2. The chest radiographs were normal (stage 0) in
17.8% of patients, stage I in 53.6%, and stage II
in 28.6%. Neither stage III nor IV was found on
chest radiographs in this series.
Gallium-67 scan
Gallium-67 scan was performed in 40 of the 56
patients. The lambda sign, i.e. increased uptake
in the bilateral hilar lymph nodes, was found in
30 (75%) patients, while the panda sign, i.e. in-
creased uptake in the lacrimal glands, was noted
in four (10%).
Skin manifestations
Erythema nodosum was the most common cuta-
neous manifestation. Fifteen of 56 (26.8%) patients
had skin lesions, including nine with erythema
nodosum in the lower extremities. Six patients
presented with erythematous nodular lesions,
which developed over the cheeks in five and fore-
head in one.
Ocular manifestations
Eleven (19.6%) patients had ocular involvement.
Among them, eight presented with panuveitis,
two with nodular scleritis and one with retinal
vasculitis.
Articular manifestations
Ten (17.8%) patients presented with arthralgia
or arthritis followed by pulmonary symptoms. The
involved joints included the ankle (5 patients),
knee (2), both wrists (2) and bilateral proximal
interphalangeal joints of the hands (1). No bony
destruction was found on radiography in these
patients.
Involvement of other organs
Neurosarcoidosis was demonstrated by biopsy of
a pituitary mass in one female patient. Another
woman presented with first degree atrioventri-
cular block, which progressed to complete atrio-
ventricular block 3 years later. Gallium-67 scan
showed increased uptake in the heart, bilateral
hilar lymph nodes and lungs in this patient.
Pathologic findings of biopsy specimens
Biopsies of affected organs were performed in
48 of 56 patients. The pathologic findings showed
noncaseating epithelioid and giant cell granulo-
mas. The most common sources of positive biop-
sy specimens were the intrathoracic lymph nodes
(39 patients), followed by skin (4) and lung (2).
Other sites of positive biopsies included the nod-
ular scleritis (2 patients), extrathoracic lymph
Table 3. Organ involvement in patients with
sarcoidosis
Involved organ n (%)0
Lung only 25 (44.6)
Lung + skin 07 (12.5)
Lung + skin + joints 06 (10.7)
Lung + joints + eyes 4 (7.1)
Lung + peripheral lymph nodes 4 (7.1)
Eyes only 3 (5.4)
Lung + eyes 3 (5.4)
Skin + eyes 1 (1.8)
Lung + heart 1 (1.8)
Central nervous system 1 (1.8)
Skin only 1 (1.8)
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nodes (3), and pituitary gland (1). Forty-six pa-
tients (82.1%) had a positive biopsy from a single
organ site and five (8.9%) had positive findings
from two organ sites.
Laboratory findings
Elevation of serum calcium (> 11 mg/dL) was
noted in only six (20%) of 30 patients whose se-
rum calcium data were available. Four of them were
asymptomatic and two had symptomatic hyper-
calcemia (consciousness change), elevated plasma
creatinine and nephrocalcinosis.
The mean level of sACE at disease present-
ation was 26.27 ± 1.59 IU/L (range, 11.8–51.9
IU/L; upper limit of normal, 21.4 IU/L). sACE was
elevated in 72.5% (29/40) of patients at disease
onset, and declined to within the normal range
in 50% (20/40) of patients after remission. Ele-
vation of sACE was significantly greater in pa-
tients with lung involvement (stage I and stage
II) (27.98 ± 1.71 IU/L vs. 18.2 ± 2.76 IU/L; p <
0.01) (Figure 1). No significant difference in sACE
level was found between patients with stage I
and stage II disease. No significant association of
sACE level with age, gender, extrapulmonary man-
ifestations or outcome of treatment was found.
In 20 of the 40 patients, sACE level declined sig-
nificantly after treatment (24.75 ± 1.53 IU/L vs.
16.33 ± 1.21 IU/L; p < 0.05) (Figure 2A). More-
over, sACE level paralleled clinical disease activity
(Figure 2B).
Disease course
Three patients were lost to follow-up. Spontane-
ous remission occurred in 11 (20.7%) of the re-
maining 53 patients, and complete remission af-
ter treatment with corticosteroid or other immu-
nosuppressive agents, including methotrexate,
cyclosporine and cyclophosphamide, occurred
in 17 (32.1%) patients (Table 4). Persistent symp-
toms or bilateral hilar lymphadenopathy on
serial chest radiographs was noted in 25 (47.2%)
patients.
Discussion
Sarcoidosis is still considered rare in Taiwan, and
studies of the relationship among sACE, clinical
manifestations and treatment outcome have not
Figure 2. (A) Change in serum angiotensin converting enzyme (sACE) levels in eight sarcoidosis patients from disease onset to remission.
The three horizontal lines in each vertical line represent the maximum, median and minimal values, respectively. (B) Serial changes in
sACE levels in five sarcoidosis patients in the active phase, partial remission phase and at relapse.
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Figure 1. Serum angiotensin converting enzyme (sACE) level in sarcoidosis patients
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been previously reported. In this study, there was
a higher proportion of females (76.8%) (Table
2). The mean age at disease onset was 47 years,
which is much older than the mean of 36 years
reported in a study of white patients by Baugh-
man et al,8 but similar to the mean age of 41.5
years in Japanese patients reported by Pietinalho
et al,9 and the 47.2 years in a study of Chinese pa-
tients by Wang et al.10 The Asian population seems
to have an older age at disease onset. Analysis of
the seasonal differences at disease onset in this
study showed a predominance in winter (39.3%)
and early spring (21.4%), with minimal occur-
rence in autumn. This finding is consistent with
studies by Newman et al1 and Bardinas et al.11 In
some small series, different seasonal clusters were
reported; 70% of cases in Greece were identified
between March and May every year,6 50% of
diagnoses in Spain were made between April and
June,11 and most cases in Japan occurred during
June and July.12 The difference in seasonal cluster-
ing implies that environmental factors may be im-
portant in the etiology of the disease.
In this series, the major clinical features includ-
ed pulmonary symptoms, erythema nodosum,
uveitis and arthralgia/arthritis, which are consist-
ent with the previous reports of Perng et al3 and
Baughman et al.8 However, more ophthalmic (9
females, 2 males) and cutaneous (10 females, 5
males) involvements were noted in females in
this study. This is consistent with the finding by
Baughman et al that pulmonary and ocular involve-
ment followed by erythema nodosum predominat-
ed in a group of female patients in the U.S.8 The
3.6% incidence of Löfgren’s syndrome, i.e. fever,
arthritis/arthralgia, hilar adenopathy and erythe-
ma nodosum, in this study is lower than the range
of 8.4–19.1% in previous reports.6,13 The majority
of our patients (44.6%) presented with isolated
pulmonary involvement, followed by pulmonary
involvement combined with cutaneous manifes-
tations (12.5%), and pulmonary and cutaneous
manifestations with articular involvement (10.7%)
(Table 3). None of the patients in this series were
in an advanced clinical stage based on chest radio-
graphs, which is similar to findings in a report from
China.10 In contrast, advanced clinical stage was
found in 9–15% of white patients.7,8 The milder
pulmonary involvement in this series compared to
those series7,8 suggests that race might be a con-
tributory factor.
About 5–10% of systemic sarcoidosis present-
ed as neurosarcoidosis.1,14 However, the incidence
of isolated neurosarcoidosis was estimated at
less than 0.2 per 1,000,000 among whites.14 In
this series, only one female patient presented with
isolated central nervous system involvement. This
patient had a good response to treatment with
steroid and methotrexate. Another female patient
developed cardiac sarcoidosis with arrhythmias
developing after being free of pulmonary symp-
toms (stage II) for half a year. Her condition wors-
ened to complete atrioventricular block 3 years later
despite aggressive treatment.
The laboratory findings in this series are simi-
lar to those reported in previous ones,1,5,6,8 In
sarcoidosis, ACE is produced by epithelioid cells
and alveolar macrophages at the periphery of
granulomas in response to an ACE-inducing fac-
tor released by T-lymphocytes.15 In this study, sACE
was found to be markedly increased in 72.5% of
active sarcoidosis patients. Increased levels of ACE
Table 4. Therapeutic agents used in patients with complete remission (n = 28) and persistent/
progressive disease (n = 25)
Therapeutic agent Complete remission, n (%) Persistent/progressive disease, n (%)
No treatment 11 (20.7) 4 (7.5)
Corticosteroids 11 (20.7) 10 (18.9)
Corticosteroids + methotrexate 06 (11.3) 07 (13.2)
Corticosteroids + other immunosuppressants* 0 (0.0) 4 (7.5)
*Other immunosuppressants = cyclosporine, cyclophosphamide.
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have also been reported in nonsarcoid disorders
and are neither pathognomonic nor diagnostic
for the disease.16,17 Shigehara et al reported that
sACE correlated well with the serum concentration
of interleukin-12, which may be a useful clinical
marker of pulmonary sarcoidosis.18 In this study,
significantly higher levels of sACE were found in
the active stage than in the remission stage (p <
0.05, Figure 2A). Serial measurements of sACE can
be used to evaluate therapeutic efficacy and to pre-
dict disease recurrence. Moreover, the levels of
sACE paralleled clinical disease activity (Figure
2B). Significantly higher levels of sACE were found
in patients with lung involvement (p < 0.01; Fig-
ure 1). Therefore, a higher sACE level in the active
stage should lead to suspicion of pulmonary in-
volvement and should also be considered as an
indicator for aggressive treatment. However, no
significant association was found between sACE
and extrapulmonary manifestations or treatment
outcome.
Forty of the 56 patients had undergone gallium-
67 scan. Seventy-five percent of these patients
showed an area of increased uptake in bilateral hi-
lar lymph nodes (lambda sign), and 10% showed
increased uptake in the lacrimal glands and parot-
id glands and/or submandibular glands (panda
sign). Sulavik et al found the lambda sign in 79%
of sarcoidosis patients and the panda sign in
72%.19 However, gallium-67 scan had no diagnos-
tic value in sarcoidosis if there were no associated
clinical manifestations or pathologic evidence.18.19
The disease course and prognosis of sarcoido-
sis may vary considerably among different geo-
graphical regions. The relationship between disease
course and prognosis in different countries might
be attributable to genetic and environmental
factors.5 In this study, only 20.7% of patients had
spontaneous remission, and 32.1% showed
remission after treatment with corticosteroid or
other immunosuppressive agents (Table 4). Per-
sistent symptoms or bilateral hilar lymphadeno-
pathy on serial chest radiographs was noted in
47.2% of patients. Acute onset with erythema no-
dosum or asymptomatic bilateral hilar lymphade-
nopathy usually heralds a self-limiting course,
whereas an insidious onset, with multiple extrapul-
monary lesions, may be followed by relentless, pro-
gressive fibrosis of the lungs and other organs.5,20
Complete remission occurred in nearly half of
the patients in this study, and this finding is con-
sistent with data in whites.20 Some studies have
found that African-American patients had a higher
rate of extrapulmonary involvement, chronic pro-
gressive disease, worse long-term prognosis, and
higher rate of relapse.5,21 Patients with extrapulmo-
nary manifestations responded poorly to standard
medical treatment.
In conclusion, the clinical features in our pa-
tients were similar to those reported in studies of
whites, although our patients had lower inci-
dences of Löfgren’s syndrome and advanced
pulmonary involvement did not occur. Similar to
Chinese and Japanese patients with sarcoidosis,
the age of disease onset was also older in our pa-
tients than in whites. sACE levels, which decreased
significantly after corticosteroid treatment with/
without immunosuppressants, paralleled clinical
remission. Higher sACE levels were found in sar-
coid patients with lung involvement. Our results
suggest the existence of interethnic differences in
clinical manifestation and disease outcome, but a
large prospective cohort study including an immu-
nogenetic investigation would be needed to verify
this hypothesis.
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